Morgan Stanley on United Therapeutics Corp. (UTHR): project Tyvaso '2030/2035 risk-adjusted sales in IPF of $1.2bn/$2.5bn'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq futures slip on chip weakness; S&P 500 holds gains
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
| United Therapeutics Corp (NASDAQ: UTHR) | Delayed: 608.49 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $608.49 | 52 Week High | $164.04 | |||
| Open | $608.49 | 52 Week Low | $97.52 | |||
| Day High | $608.49 | P/E | 111.24 | |||
| Day Low | $608.49 | EPS | $5.47 | |||
| Volume | 28 | |||||
